The purpose of this study is to evaluate the therapeutic efficacy of inhaled recombinant
human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (PAP) due to
partial dysfunction of the GM-CSF receptor.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborators:
Genzyme, a Sanofi Company Virginia Commonwealth University